Last reviewed · How we verify
Molar Sodium Lactate
Molar Sodium Lactate is a buffering agent that increases blood pH and provides lactate as a metabolic substrate to counteract acidosis.
Molar Sodium Lactate is a buffering agent that increases blood pH and provides lactate as a metabolic substrate to counteract acidosis. Used for Metabolic acidosis correction in critical care settings, Lactic acidosis management.
At a glance
| Generic name | Molar Sodium Lactate |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Drug class | Alkalinizing agent / Buffer solution |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Metabolic Disorders |
| Phase | Phase 3 |
Mechanism of action
Sodium lactate acts as an alkalinizing agent by increasing serum bicarbonate and pH, while simultaneously providing lactate that can be metabolized by the liver and muscles for energy. It is used to correct metabolic acidosis by shifting the acid-base balance toward alkalinity and supplying an alternative fuel source that reduces reliance on anaerobic metabolism.
Approved indications
- Metabolic acidosis correction in critical care settings
- Lactic acidosis management
Common side effects
- Hypernatremia
- Fluid overload
- Hyperkalemia (if co-administered with potassium-sparing agents)
- Phlebitis at infusion site
Key clinical trials
- Therapeutic Effect of Microfragmented Adipose Tissue (Lipogems) Injection on Maximum Interincisal Opening Versus Injectable Platelet-rich Plasma (PRP) for the Treatment of Anterior Disc Displacement With Reduction : A Randomized Clinical Trial (PHASE2, PHASE3)
- Molar Sodium Lactate Filling in Severe Meningeal Hemorrhage (PHASE3)
- Hypertonic Lactate After Cardiac Arrest (PHASE2)
- Sodium Lactate and Brain Relaxation (LSD) (PHASE3)
- The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy (NA)
- 0.5M Na Lactate Solution in Acute Heart Failure (AHF) (PHASE2)
- Preventive Sodium Lactate and Traumatic Brain Injury (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |